FOX 5 spoke exclusively with a participant in a study for a new injectable drug to prevent HIV. Emory University medical ...
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
A new HIV prevention method, Lenacapavir, administered as a twice-yearly injection, has demonstrated superior results ...
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...
Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
A deal that allows manufacturers to produce generic versions of lenacapavir has left out some Eastern European countries ...
Courtney Breen, an analyst from Bernstein, has initiated a new Buy rating on Gilead Sciences (GILD).Don't Miss our Black Friday Offers:Unlock ...